TipHub

1,001.45

+16.06 +1.63%

29 Jul 2026

NSE Listed · Pharmaceuticals

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-06-18
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Orchid Pharma Limited (ORCHPHARMA)

Volume: 47,133Avg Vol 1W: 61,278Avg Vol 1M: 3,03,06352W Range:4801,119.8
Market Cap₹5,079 Cr
Current Price₹1,001.45
Previous Close₹985.39
High / Low (52w)₹1,119.8 / ₹480
Volume47,133
Avg Vol (1W)61,278
Avg Vol (1M)3,03,063
Stock P/E213.53
Book Value₹253.9
Dividend Yield0%
ROE2.11%
ROA1.1%
Revenue (TTM)
Revenue Growth12.52%
Profit Margin2.51%
Total Debt₹132 Cr
Shares Outstanding5 Cr
Face Value₹10
EPS (TTM)₹4.69
P/B3.94
Debt / Equity0.28
50 DMA₹925.35
200 DMA₹752.15
Day change+1.63%
SurveillanceLT-ASM · ASM 1
Price Chart
1,001.45 43.25% · 1Y
111948232.6L
2025-07-29
2026-07-29

20-day avg volume: 3.3L shares

Pros
  • Company is almost debt-free.
  • Revenue grew 15% YoY.
Cons
  • Stock trades at a high P/E of 214.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹244 Cr₹223 Cr₹217 Cr₹237 Cr₹173 Cr₹194 Cr₹207 Cr₹238 Cr
EBITDA₹32 Cr₹29 Cr₹26 Cr₹23 Cr₹17 Cr₹0 Cr₹-2 Cr₹25 Cr
Net Profit₹29 Cr₹27 Cr₹21 Cr₹22 Cr₹15 Cr₹-6 Cr₹-13 Cr₹24 Cr
EPS
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹223 Cr₹217 Cr₹237 Cr₹949 Cr₹173 Cr₹194 Cr₹207 Cr₹238 Cr
EBITDA₹29 Cr₹28 Cr₹32 Cr₹110 Cr₹21 Cr₹6 Cr₹4 Cr₹33 Cr
Net Profit₹26 Cr₹24 Cr₹28 Cr₹100 Cr₹18 Cr₹2 Cr₹-6 Cr₹31 Cr
EPS19.65
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹3,125 Cr₹3,077 Cr₹1,460 Cr₹1,237 Cr₹1,111 Cr₹1,225 Cr₹1,554 Cr₹1,688 Cr
Total Liabilities₹3,917 Cr₹3,781 Cr₹694 Cr₹584 Cr₹463 Cr₹537 Cr₹384 Cr₹421 Cr
Equity₹-792 Cr₹-704 Cr₹766 Cr₹653 Cr₹647 Cr₹689 Cr₹1,169 Cr₹1,267 Cr
Total Debt
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹16 Cr₹16 Cr₹70 Cr₹19 Cr₹94 Cr₹19 Cr₹125 Cr₹20 Cr
Investing₹-28 Cr₹45 Cr₹167 Cr₹67 Cr₹113 Cr₹-31 Cr₹-312 Cr₹-27 Cr
Financing₹33 Cr₹0 Cr₹-250 Cr₹-165 Cr₹-217 Cr₹31 Cr₹167 Cr₹25 Cr
Free Cash Flow₹16 Cr₹16 Cr₹70 Cr₹19 Cr₹94 Cr₹19 Cr₹125 Cr₹20 Cr
Shareholding
Promoter 69.84% Institutions 21.55% Public 8.61%
Efficiency & Working Capital
ROCE3.2%
Interest Coverage7.4
Dividend Payout
Debtor Days96 d
Inventory Days129 d
Payable Days88 d
Cash Conversion Cycle137 d
Working Capital Days225 d
Shareholding Details

As of 2026-06-30

Promoter69.8%
FII0.8%
DII20.7%
Institutions21.6%
Public8.6%
Promoter Pledge0%
No. of Shareholders33,433
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters72.4%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%69.8%
FIIs8.1%4.1%2%1.4%1.9%2.5%2.7%1.4%1.6%1.2%0.9%0.8%
DIIs9.9%14.5%17.7%18.9%18.3%19%20.1%19.4%19%19.4%20.2%20.7%
Public9.6%11.5%10.5%9.8%9.9%8.6%7.4%9.3%9.6%9.6%9%8.6%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders29,19736,93136,72034,69536,36334,15834,30339,82738,15535,70935,11833,433
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Dhanuka Laboratories LimitedShareholding of Promoter and Promoter Group69.8%3.54 Cr
Quant Mutual Fund - Quant Small Cap FundPublic Shareholding6.8%34,65,947
Kotak Mahindra Trustee Co Ltd A/c Kotak Consumption Fund And 7 OthersPublic Shareholding4.6%23,35,445
Uti Small Cap Fund And 3 OthersPublic Shareholding3.5%17,55,037
Invesco India Contra Fund And 2 OthersPublic Shareholding2.9%14,56,510
Bandhan Small Cap Fund And 5 OthersPublic Shareholding1.5%7,76,976
Board of Directors
NameDesignationYear
R G AgarwalChairman(Non Exe)&Dir(Non-Ind)2025
Manish DhanukaExecutive Director & MD2025
Mridul DhanukaE D & Wholetime Director2025
Arjun DhanukaNon-Exec & Non-Independent Dir2025
Dharam VirIndependent Non Exe. Director2025
Manoj GoyalIndependent Non Exe. Director2025
Tanu SinglaIndependent Non Exe. Director2025
Shubha SinghIndependent Non Exe. Director2025
Kapil DayyaCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr
Segments — Geography
RegionRevenueShare
India₹181 Cr19.9%
Rest of the world₹728 Cr80.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹101505151
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025558008233
20255660000566
2025-130000-13
Insider / Designated-Person Trades

3 recent disclosure(s)

DHANUKA LABORATORIES LIMITEDDisposal · 13,00,000
Dhanuka Laboratories LimitedRevoke · 80,00,015
Dhanuka Laboratories LimitedRevoke · 1,20,00,022
Substantial Acquisitions (SAST)

6 disclosure(s)

Market26/12/2023 · 15,385
Market22/12/2023 · 69,782
Invocation19/12/2023 · 85,167
Market11/12/2023 - 15/12/2023 · 10,00,000
Off Market28/11/2023 · 13,00,000
Release of Shares19/01/2022 ·
Company Information
Incorporated1992
ChairmanR G Agarwal
AuditorSinghi & Co
Investor Email[email protected]
🌐 www.orchidpharma.com

📍 Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road, Chennai, Tamil Nadu, 600034

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search